DE69112634D1 - IMMUNOGENOUS COMPLEXES, IN PARTICULAR ISCOMS. - Google Patents

IMMUNOGENOUS COMPLEXES, IN PARTICULAR ISCOMS.

Info

Publication number
DE69112634D1
DE69112634D1 DE69112634T DE69112634T DE69112634D1 DE 69112634 D1 DE69112634 D1 DE 69112634D1 DE 69112634 T DE69112634 T DE 69112634T DE 69112634 T DE69112634 T DE 69112634T DE 69112634 D1 DE69112634 D1 DE 69112634D1
Authority
DE
Germany
Prior art keywords
pct
iscoms
quil
fractions
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69112634T
Other languages
German (de)
Other versions
DE69112634T2 (en
Inventor
Gideon Kersten
Arjen Spiekstra
Gerrit Van De Werken
Eduard Beuvery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of DE69112634D1 publication Critical patent/DE69112634D1/en
Application granted granted Critical
Publication of DE69112634T2 publication Critical patent/DE69112634T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/256Polyterpene radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PCT No. PCT/NL91/00211 Sec. 371 Date Apr. 19, 1993 Sec. 102(e) Date Apr. 19, 1993 PCT Filed Oct. 23, 1991 PCT Pub. No. WO92/06710 PCT Pub. Date Apr. 30, 1992The invention relates to immunogenic complexes such as two-dimensional lamellae having a honeycomb structure and in particular three-dimensional iscoms, which immunogenic complexes are composed of at least one sterol, one saponin and, in the case of iscoms, also a phospholipid and also, optionally, at least one antigen generating an immune reaction. The saponin used is at least one of the fractions which are derived from Quil A by means of hydrophobic interaction chromatography and have the designations QA 1 to QA 23, as is shown in the figure by the numerals 1 to 23. Preferably, the saponin used is one or more of the fractions derived from Quil A having the designations QA 3, QA 17 and QA 23. As well as relating to the immunogenic complex, the invention also relates to the specific method of preparation of the relevant Quil A fractions, to vaccines which contain such immunogenic complexes and to kits which contain, on the one hand, an (empty) immunogenic complex and, on the other hand, one or more antigenic proteins or peptides having a hydrophobic fragment which may or may not have been synthetically introduced.
DE69112634T 1990-10-23 1991-10-23 IMMUNOGENOUS COMPLEXES, IN PARTICULAR ISCOMS. Expired - Lifetime DE69112634T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9002314A NL9002314A (en) 1990-10-23 1990-10-23 IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
PCT/NL1991/000211 WO1992006710A1 (en) 1990-10-23 1991-10-23 Immunogenic complexes, in particular iscoms

Publications (2)

Publication Number Publication Date
DE69112634D1 true DE69112634D1 (en) 1995-10-05
DE69112634T2 DE69112634T2 (en) 1996-02-08

Family

ID=19857870

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69112634T Expired - Lifetime DE69112634T2 (en) 1990-10-23 1991-10-23 IMMUNOGENOUS COMPLEXES, IN PARTICULAR ISCOMS.

Country Status (10)

Country Link
US (1) US5620690A (en)
EP (1) EP0555276B1 (en)
AT (1) ATE127024T1 (en)
CA (1) CA2094600C (en)
DE (1) DE69112634T2 (en)
DK (1) DK0555276T3 (en)
ES (1) ES2075964T3 (en)
GR (1) GR3017778T3 (en)
NL (1) NL9002314A (en)
WO (1) WO1992006710A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677977B2 (en) * 1992-10-30 1997-05-15 Seed Capital Investments (Sci) B.V. Cultured cells of Quillaja sp.
NL9301690A (en) * 1993-08-12 1995-04-18 Seed Capital Investments Compounds with adjuvant activity.
AU1077795A (en) * 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
SE9600648D0 (en) * 1996-02-21 1996-02-21 Bror Morein Receptor binding unit
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
ES2327693T3 (en) * 1997-08-29 2009-11-02 Antigenics Inc. COMPOSITIONS THAT INCLUDE THE QS-21 ADJUSTER AND EXCIPIENT POLYSORBATE OR CYCLODEXTRINE.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2004528321A (en) 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ Polynucleotide binding complexes containing sterols and saponins
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
SE0202110D0 (en) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
DE60330257D1 (en) * 2002-10-02 2010-01-07 Nordic Vaccine Technology As COMPOSITION FOR VACCINATION
SE0300795D0 (en) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (en) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
PL1838341T3 (en) 2005-01-20 2014-04-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
WO2006112339A1 (en) * 2005-04-14 2006-10-26 Matsushita Electric Industrial Co., Ltd. Method for determination of hemoglobin derivative, and reagent composition, assay kit, analysis device and analysis system for use in the method
AU2010205717A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
CA2850296C (en) 2011-10-03 2021-01-12 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CN114796474A (en) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 Vaccine compositions with improved stability and immunogenicity
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (en) * 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
SE8405493D0 (en) * 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
EP0231039B1 (en) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins

Also Published As

Publication number Publication date
GR3017778T3 (en) 1996-01-31
DK0555276T3 (en) 1995-09-18
WO1992006710A1 (en) 1992-04-30
ATE127024T1 (en) 1995-09-15
US5620690A (en) 1997-04-15
EP0555276B1 (en) 1995-08-30
NL9002314A (en) 1992-05-18
CA2094600A1 (en) 1992-04-24
DE69112634T2 (en) 1996-02-08
EP0555276A1 (en) 1993-08-18
CA2094600C (en) 1998-12-08
ES2075964T3 (en) 1995-10-16

Similar Documents

Publication Publication Date Title
DE69112634D1 (en) IMMUNOGENOUS COMPLEXES, IN PARTICULAR ISCOMS.
DK602989A (en) saponin adjuvant
ZA837603B (en) Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
ES500567A0 (en) PROCEDURE FOR PREPARING VACCINATION COMPLEXES BY REACTION OF RIBONOSAL RNA AND SPECIFIC ANTIGENS.
GB9626484D0 (en) Helicobacter pylori antigenic protein preparation and immunoassays
PT584348E (en) GENETIC VACCINE FOR IMMUNODEFICIENCY VIRUS
NZ219113A (en) Hiv peptide containing epitope of the env protein
ES2138588T3 (en) COMPOSITIONS OF VACCINES CONTAINING LIPOSOMES.
HUP9903770A2 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
DE69716240D1 (en) NEW METHOD FOR VACCINATION AND VACCINE SUBSTANCES THAT CONTAIN AN EPITOP-CODING NUCLEIC ACID AND AN EPITOP-CONTAINING PEPTIDE
HUT72923A (en) Immunogenic formulation of ospc antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
ATE188484T1 (en) IMMUNOLOGICALLY HLA HOMOLOGUE HIV PROTEIN EPITOPES
ZA856655B (en) Cross-reactive and protective epitopes of circumsporozoite proteins
IL106407A0 (en) Antigens,vaccines containing them and their preparation
FI973335A0 (en) Helicobacter pylori antigen
AR020852A1 (en) LEPTOSPIRA VACCINE ANTIGENS FOR THE PREVENTION OF LEPTOSPIROSIS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition